Stereotactic Radiosurgery for Atypical (World Health Organization II) and Anaplastic (World Health Organization III) Meningiomas: Results From a Multicenter, International Cohort Study.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
15 04 2021
Historique:
received: 30 07 2020
accepted: 04 11 2020
pubmed: 21 1 2021
medline: 3 7 2021
entrez: 20 1 2021
Statut: ppublish

Résumé

Atypical and anaplastic meningiomas have reduced progression-free/overall survival (PFS/OS) compared to benign meningiomas. Stereotactic radiosurgery (SRS) for atypical meningiomas (AMs) and anaplastic meningiomas (malignant meningiomas, MMs) has not been adequately described. To define clinical/radiographic outcomes for patients undergoing SRS for AM/MMs. An international, multicenter, retrospective cohort study was performed to define clinical/imaging outcomes for patients receiving SRS for AM/MMs. Tumor progression was assessed with response assessment in neuro-oncology (RANO) criteria. Factors associated with PFS/OS were assessed using Kaplan-Meier analysis and a Cox proportional hazards model. A total of 271 patients received SRS for AMs (n = 233, 85.9%) or MMs (n = 38, 14.0%). Single-fraction SRS was most commonly employed (n = 264, 97.4%) with a mean target dose of 14.8 Gy. SRS was used as adjuvant treatment (n = 85, 31.4%), salvage therapy (n = 182, 67.2%), or primary therapy (1.5%). The 5-yr PFS/OS rate was 33.6% and 77.0%, respectively. Increasing age (hazard ratio (HR) = 1.01, P < .05) and a Ki-67 index > 15% (HR = 1.66, P < .03) negatively correlated with PFS. MMs (HR = 3.21, P < .05), increased age (HR = 1.04, P = .04), and reduced KPS (HR = 0.95, P = .04) were associated with shortened OS. Adjuvant versus salvage SRS did not impact PFS/OS. A shortened interval between surgery and SRS improved PFS for AMs (HR = 0.99, P = .02) on subgroup analysis. Radiation necrosis occurred in 34 (12.5%) patients. Five-year rates of repeat surgery/radiation were 33.8% and 60.4%, respectively. AM/MMs remain challenging tumors to treat. Elevated proliferative indices are associated with tumor recurrence, while MMs have worse survival. SRS can control AM/MMs in the short term, but the 5-yr PFS rates are low, underscoring the need for improved treatment options for these patients.

Sections du résumé

BACKGROUND
Atypical and anaplastic meningiomas have reduced progression-free/overall survival (PFS/OS) compared to benign meningiomas. Stereotactic radiosurgery (SRS) for atypical meningiomas (AMs) and anaplastic meningiomas (malignant meningiomas, MMs) has not been adequately described.
OBJECTIVE
To define clinical/radiographic outcomes for patients undergoing SRS for AM/MMs.
METHODS
An international, multicenter, retrospective cohort study was performed to define clinical/imaging outcomes for patients receiving SRS for AM/MMs. Tumor progression was assessed with response assessment in neuro-oncology (RANO) criteria. Factors associated with PFS/OS were assessed using Kaplan-Meier analysis and a Cox proportional hazards model.
RESULTS
A total of 271 patients received SRS for AMs (n = 233, 85.9%) or MMs (n = 38, 14.0%). Single-fraction SRS was most commonly employed (n = 264, 97.4%) with a mean target dose of 14.8 Gy. SRS was used as adjuvant treatment (n = 85, 31.4%), salvage therapy (n = 182, 67.2%), or primary therapy (1.5%). The 5-yr PFS/OS rate was 33.6% and 77.0%, respectively. Increasing age (hazard ratio (HR) = 1.01, P < .05) and a Ki-67 index > 15% (HR = 1.66, P < .03) negatively correlated with PFS. MMs (HR = 3.21, P < .05), increased age (HR = 1.04, P = .04), and reduced KPS (HR = 0.95, P = .04) were associated with shortened OS. Adjuvant versus salvage SRS did not impact PFS/OS. A shortened interval between surgery and SRS improved PFS for AMs (HR = 0.99, P = .02) on subgroup analysis. Radiation necrosis occurred in 34 (12.5%) patients. Five-year rates of repeat surgery/radiation were 33.8% and 60.4%, respectively.
CONCLUSION
AM/MMs remain challenging tumors to treat. Elevated proliferative indices are associated with tumor recurrence, while MMs have worse survival. SRS can control AM/MMs in the short term, but the 5-yr PFS rates are low, underscoring the need for improved treatment options for these patients.

Identifiants

pubmed: 33469655
pii: 6104456
doi: 10.1093/neuros/nyaa553
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

980-988

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Congress of Neurological Surgeons 2021.

Auteurs

Matthew J Shepard (MJ)

Department of Neurologic Surgery, University of Virginia Health System, Charlottesville, Virginia.
MD Anderson Cancer Center, Houston, Texas.

Zhiyuan Xu (Z)

Department of Neurologic Surgery, University of Virginia Health System, Charlottesville, Virginia.

Kathryn Kearns (K)

Department of Neurologic Surgery, University of Virginia Health System, Charlottesville, Virginia.

Chelsea Li (C)

Department of Neurologic Surgery, University of Virginia Health System, Charlottesville, Virginia.

Ajay Chatrath (A)

Department of Neurologic Surgery, University of Virginia Health System, Charlottesville, Virginia.

Kimball Sheehan (K)

Department of Neurologic Surgery, University of Virginia Health System, Charlottesville, Virginia.

Darrah Sheehan (D)

Department of Neurologic Surgery, University of Virginia Health System, Charlottesville, Virginia.

Andrew Faramand (A)

Center of Image Guided Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Ajay Niranjan (A)

Center of Image Guided Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Hideyuki Kano (H)

Center of Image Guided Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Jason Gurewitz (J)

Departments of Neurosurgery and Medical Physics.

Kenneth Bernstein (K)

NYU Langone Health System, New York, New York.

Roman Liscak (R)

Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic.

Khumar Guseynova (K)

Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic.

Inga S Grills (IS)

Department of Radiation Oncology, Beaumont Health, Royal Oak, Michigan.

Jacob S Parzen (JS)

Department of Radiation Oncology, Beaumont Health, Royal Oak, Michigan.

Christopher P Cifarelli (CP)

Department of Neurologic Surgery, West Virginia University, Morgantown, West Virginia.

Azeem A Rehman (AA)

Department of Neurologic Surgery, West Virginia University, Morgantown, West Virginia.

Ahmet Atik (A)

Department of Neurologic Surgery, Cleveland Clinic Foundation, Cleveland, Ohio.

Joshua Bakhsheshian (J)

Departments of Neurologic Surgery, University of Southern California, Los Angeles, California.

Gabriel Zada (G)

Departments of Neurologic Surgery, University of Southern California, Los Angeles, California.

Eric Chang (E)

Department of Radiation Oncology, University of Southern California, Los Angeles, California.

Steven Giannotta (S)

Departments of Neurologic Surgery, University of Southern California, Los Angeles, California.

Herwin Speckter (H)

Centro Gamma Knife Dominicano, CEDIMAT, Plaza de la Salud, Santo Domingo, Dominican Republic.

Hsiu-Mei Wu (HM)

Department of Radiology, Taipei Veteran General Hospital, Taipei, Taiwan.
National Yang-Ming University School of Medicine, Taipei, Taiwan.

Douglas Kondziolka (D)

Departments of Neurosurgery and Medical Physics.

John G Golfinos (JG)

Departments of Neurosurgery and Medical Physics.

David Mathieu (D)

Department of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada.

Cheng-Chia Lee (CC)

Department of Neurosurgery, Taipei Veteran General Hospital, Taipei, Taiwan.
National Yang-Ming University School of Medicine, Taipei, Taiwan.

Ronald E Warnick (RE)

Department of Neurologic Surgery, Mayfield Clinic, Cincinnati, Ohio.

L Dade Lunsford (LD)

Center of Image Guided Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Jason P Sheehan (JP)

Department of Neurologic Surgery, University of Virginia Health System, Charlottesville, Virginia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH